Time filter

Source Type

Within a consortium, led by Oryzon, that will have a 1.3M USD aggregated budget BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - December 21, 2016) - Oryzon Genomics ( : ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Company will receive a new grant in the form of a loan with interest rate granted, from the Ministry of Economy and Competitiveness, Government of Spain and FEDER Funds from the European Union and included under the RETOS Collaboration 2016 program. Oryzon will receive approximately 0.8M USD (multiyear disbursements) for further development of its epigenetic inhibitors against inflammatory indications. This grant (RTC-2016-4955-1) will cover the partial funding of a project entitled "Epigenetic regulation of the inflammatory response" that is currently being carried out under the leadership of Oryzon in collaboration with various well renowned academic institutions such as the Cajal Institute (National Spanish Research Council, CSIC, Madrid), the López Neira Institute (CSIC, Granada), Bosch i Gimpera Foundation (University of Barcelona) and the Autonomous University of Barcelona. The project has a 33 month duration, starting April 1, 2016 and ending December 31, 2018, and the aggregated budget of the project is approximately 1.3M USD. The public institutions will receive a non-reimbursable grant to develop different activities to assess the potential of Oryzon's drugs on inflammatory diseases for a total amount exceeding 0.4 M USD. Carlos Buesa, President and Chief Executive Officer of Oryzon, commented: "This private-public consortium will set up useful tools and approaches to assess the therapeutic potential of LSD1 inhibitors and other epigenetic modulators in inflammatory and autoimmune diseases, a field that Oryzon is already exploring with ORY-2001, its first in class epigenetic program in Multiple Sclerosis. ORY-2001 is expected to finish Phase I in the next months." Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by +20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com. This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

De Ron A.M.,National Spanish Research Council | Rodino A.P.,National Spanish Research Council | Santalla M.,National Spanish Research Council | Gonzalez A.M.,National Spanish Research Council | And 3 more authors.
Frontiers in Plant Science | Year: 2016

Rapid and uniform seed germination and seedling emergence under diverse environmental conditions is a desirable characteristic for crops. Common bean genotypes (Phaseolus vulgaris L.) differ in their low temperature tolerance regarding growth and yield. Cultivars tolerant to low temperature during the germination and emergence stages and carriers of the grain quality standards demanded by consumers are needed for the success of the bean crop. The objectives of this study were (i) to screen the seedling emergence and the phenotypic response of bean germplasm under a range of temperatures in controlled chamber and field conditions to display stress-tolerant genotypes with good agronomic performances and yield potential, and (ii) to compare the emergence of bean seedlings under controlled environment and in open field conditions to assess the efficiency of genebanks standard germination tests for predicting the performance of the seeds in the field. Three trials were conducted with 28 dry bean genotypes in open field and in growth chamber under low, moderate, and warm temperature. Morpho-agronomic data were used to evaluate the phenotypic performance of the different genotypes. Cool temperatures resulted in a reduction of the rate of emergence in the bean genotypes, however, emergence and early growth of bean could be under different genetic control and these processes need further research to be suitably modeled. Nine groups arose from the Principal Component Analysis (PCA) representing variation in emergence time and proportion of emergence in the controlled chamber and in the open field indicating a trend to lower emergence in large and extra-large seeded genotypes. Screening of seedling emergence and phenotypic response of the bean germplasm under a range of temperatures in controlled growth chambers and under field conditions showed several genotypes, as landraces 272, 501, 593, and the cultivar Borlotto, with stress-tolerance at emergence, and high yield potential that could be valuable genetic material for breeding programs. Additionally, the potential genetic erosion in genebanks was assessed. Regarding bean commercial traits, under low temperature at sowing time seed reached larger size, and crop yield was higher compared to warmer temperatures at the sowing time. Therefore, early sowing of bean is strongly recommended. © 2016 De Ron, Rodiño, Santalla, González, Lema, Martín and Kigel.

Pacheco-Labrador J.,National Spanish Research Council | Martin M.P.,National Spanish Research Council
IEEE Transactions on Geoscience and Remote Sensing | Year: 2014

We report the characterization and correction of nonlinear responses of a commercial field portable spectroradiometer intended to be used to monitor vegetation physiology. Calibration of photoresponse allowed the successful correction of spectral data and the modeling of biases in reflectance at different levels of the dynamic range. Finally, the impact of nonlinearities on a spectral estimator of photosynthetic status, the photochemical reflectance index (PRI) is discussed. Significance of the biases proved that, although nonlinearity can potentially affect reflectance along most of the dynamic range of the instrument, experimental uncertainties can limit its impact. Nonlinearity biased PRI by affecting the reference band of the index and suggested unreal changes on plant physiology. Results show that nonlinearity could be a significant problem in field spectroscopy, especially in the case of spectroradiometers integrated in unattended systems to monitor vegetation responses to radiation. An automatic adjustment of integration time to reach only a certain level of the dynamic range may reduce nonlinearity effects, though may not always avoid them. We conclude that linearity characterization is necessary to understand impacts and correct potential biases. © 1980-2012 IEEE.

Loading National Spanish Research Council collaborators
Loading National Spanish Research Council collaborators